NEDD4 Plays Roles in the Maintenance of Breast Cancer Stem Cell Characteristics

Triple-negative breast cancer (TNBC) is the most aggressive type with poor prognosis among the breast cancers and has a high population of cancer stem cells (CSCs), which are the main target to cure and inhibit TNBC. In this study, we examined the role of neural precursor cell expressed developmenta...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 1680
Main Authors Jeon, Seon-Ae, Kim, Dong Wook, Lee, Da-Bin, Cho, Je-Yoel
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 02.09.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Triple-negative breast cancer (TNBC) is the most aggressive type with poor prognosis among the breast cancers and has a high population of cancer stem cells (CSCs), which are the main target to cure and inhibit TNBC. In this study, we examined the role of neural precursor cell expressed developmentally downregulated protein 4 (NEDD4) in the proliferation, migration, and CSC characteristics of MDA-MB-231, a TNBC cell line. Interestingly, the Kaplan–Meier plotter showed that the survival rate of patients with a higher expression level of NEDD4 was significantly shorter than those of patients with a lower expression only in relatively aggressive and higher stage (grade 3) breast cancer patients. The knockdown of NEDD4 drastically decreased the proliferation, migration, and mammosphere formation in MDA-MB-231 cells. A proteomic analysis revealed the alteration of CSC-related proteins; notably, Myc targets stem cell-like signatures in siNEDD4-treated MDA-MB-231. An immunoassay also showed that the expression and the activity of breast CSC markers are decreased in NEDD4-deleted MDA-MB-231. Taken together, these results indicate that NEDD4 is involved in the maintenance of populations and characteristics of breast CSCs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Harsha Gowda, The University of Queensland, Australia
Reviewed by: Prasanna Ekambaram, University of Pittsburgh, United States; Antonietta Santoro, University of Salerno, Italy
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.01680